Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: J Drug Issues. 2020 Jul 4;50(4):524–537. doi: 10.1177/0022042620936655

Table 2.

Number of DSM-5 CUD symptoms endorsed by participants (N = 99)

Number of DSM-5 CUD symptoms
endorsed
N (%)
0 1 (1%)
1 8 (8.1%)
2 8 (8.1%)
3 11 (11.1%)
4 17 (17.2%)
5 16 (16.2%)
6 14 (14.1%)
7 14 (14.1%)
8 4 (4%)
9 3 (3%)
10 2 (2%)
11 1 (1%)